HSBC Holdings’s Verona Pharma VRNA Stock Holding History

HSBC Holdings’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,041	Closed	-$259K	–	3073
2022 Q4	$259K	Sell	10,041 -5,000	-33%	-$66.6K	﹤0.01%	2637
2022 Q3	$158K	Hold	15,041	–	–	﹤0.01%	2692
2022 Q2	$69K	Hold	15,041	–	–	﹤0.01%	3099
2022 Q1	$79K	Hold	15,041	–	–	﹤0.01%	3158
2021 Q4	$102K	Hold	15,041	–	–	﹤0.01%	3139
2021 Q3	$83K	Hold	15,041	–	–	﹤0.01%	2899
2021 Q2	$101K	Hold	15,041	–	–	﹤0.01%	2848
2021 Q1	$124K	Hold	15,041	–	–	﹤0.01%	2616
2020 Q4	$105K	Buy	+15,041	New	+$102K	﹤0.01%	2945

Other funds holding VRNA

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

HSBC Holdings's VRNA Position: Q1 2023 in Review

HSBC Holdings sold out of Verona Pharma (VRNA) in Q1 2023, closing a stake of 10,041 shares — an estimated $259K sold.

HSBC Holdings first reported a position in VRNA in Q4 2020 and held it in 9 quarters. The position peaked at $259K in Q4 2022. 95 funds tracked by Wall St. Rank hold VRNA as of Q1 2023.

HSBC Holdings reported no remaining Verona Pharma position as of Q1 2023 after selling out during the quarter.
HSBC Holdings sold 10,041 Verona Pharma shares in Q1 2023, an estimated $259K.
HSBC Holdings first reported a position in Verona Pharma in Q4 2020 and held it in 9 quarters.
HSBC Holdings's Verona Pharma position peaked at $259K in Q4 2022.
95 funds tracked by Wall St. Rank held Verona Pharma as of Q1 2023.

Based on HSBC Holdings's 13F filing for Q1 2023, filed 15 May 2023.